Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
Liu D, Ma C, Lu P, Gong J, Ye D, Wang S, Peng P, Bai Y, Song Y, Chen J, Jiang O, Zhang G, Ba Y, Chen L, Pan J, Li Q, Zhang L, Gu S, Yin X, Cao B, Han W, Dong H, Guo J, Zhang H, Su H, Jiang Y, Ouyang W, Ma L, Sun Y, Zhang F, Lv J, Guo Y, Xu C, Qi J, Wang L, Wang X, Liu Z, Shen L.
Liu D, et al. Among authors: jiang o, jiang y.
Eur J Cancer. 2021 May;148:1-13. doi: 10.1016/j.ejca.2021.01.020. Epub 2021 Mar 7.
Eur J Cancer. 2021.
PMID: 33691262
Free article.
Clinical Trial.